These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30311542)

  • 1. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy.
    Angelopoulou A; Kolokithas-Ntoukas A; Papaioannou L; Kakazanis Z; Khoury N; Zoumpourlis V; Papatheodorou S; Kardamakis D; Bakandritsos A; Hatziantoniou S; Avgoustakis K
    Nanomedicine (Lond); 2018 Oct; 13(19):2435-2454. PubMed ID: 30311542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic Nanoparticles for the Delivery of Dapagliflozin to Hypoxic Tumors: Physicochemical Characterization and Cell Studies.
    Angelopoulou A; Voulgari E; Kolokithas-Ntoukas A; Bakandritsos A; Avgoustakis K
    AAPS PharmSciTech; 2018 Feb; 19(2):621-633. PubMed ID: 28924948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
    Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
    PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells.
    Lin Y; Nan J; Shen J; Lv X; Chen X; Lu X; Zhang C; Xiang P; Wang Z; Li Z
    EBioMedicine; 2020 Feb; 52():102637. PubMed ID: 31981975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754).
    Lin R; Hoerr DC; Weaner LE; Salter R
    J Labelled Comp Radiopharm; 2017 Nov; 60(13):616-623. PubMed ID: 28833358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following
    Korkmaz-Icöz S; Kocer C; Sayour AA; Kraft P; Benker MI; Abulizi S; Georgevici AI; Brlecic P; Radovits T; Loganathan S; Karck M; Szabó G
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.
    Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Popescu I; Kalaitzoglou E; Fowlkes JL; Nyman JS
    Bone; 2020 Dec; 141():115625. PubMed ID: 32890778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
    Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
    Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
    Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
    Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin extends life span in genetically heterogeneous male but not female mice.
    Miller RA; Harrison DE; Allison DB; Bogue M; Debarba L; Diaz V; Fernandez E; Galecki A; Garvey WT; Jayarathne H; Kumar N; Javors MA; Ladiges WC; Macchiarini F; Nelson J; Reifsnyder P; Rosenthal NA; Sadagurski M; Salmon AB; Smith DL; Snyder JM; Lombard DB; Strong R
    JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.
    Papadopoli D; Uchenunu O; Palia R; Chekkal N; Hulea L; Topisirovic I; Pollak M; St-Pierre J
    Neoplasia; 2021 Apr; 23(4):391-399. PubMed ID: 33784591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
    VanDerStad LR; Wyatt EC; Vaughan RA
    Diabet Med; 2024 May; 41(5):e15271. PubMed ID: 38140911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis.
    Long Q; Li L; Yang H; Lu Y; Yang H; Zhu Y; Tang Y; Liu C; Yuan J
    Int Immunopharmacol; 2022 Sep; 110():109024. PubMed ID: 35841866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin Improves Liver Function in Rats by Upregulating Asparagine Synthetase.
    Wang S; Ding Y; Dong R; Wang H; Yin L; Meng S
    Pharmacology; 2021; 106(11-12):606-615. PubMed ID: 34515223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice.
    Yildirim G; Bergamo ETP; Poudel SB; Ruff RR; Dixit M; Hu B; Mijares DQ; Witek L; Chlebek C; Harrison DE; Strong R; Miller RA; Ladiges W; Bromage TG; Rosen CJ; Yakar S
    Geroscience; 2023 Jun; 45(3):1933-1951. PubMed ID: 37166526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
    Ali A; Mekhaeil B; Biziotis OD; Tsakiridis EE; Ahmadi E; Wu J; Wang S; Singh K; Menjolian G; Farrell T; Mesci A; Liu S; Berg T; Bramson JL; Steinberg GR; Tsakiridis T
    Commun Biol; 2023 Sep; 6(1):919. PubMed ID: 37684337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex of TNF-α and Modified Fe
    Teo P; Wang X; Chen B; Zhang H; Yang X; Huang Y; Tang J
    Cancer Biother Radiopharm; 2017 Dec; 32(10):379-386. PubMed ID: 29265918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic hyperthermia and pH-responsive effective drug delivery to the sub-cellular level of human breast cancer cells by modified CoFe
    Oh Y; Moorthy MS; Manivasagan P; Bharathiraja S; Oh J
    Biochimie; 2017 Feb; 133():7-19. PubMed ID: 27916642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.